Sanofi India Ltd Q3CY25 – When French Elegance Meets Indian Pharma Price Control (Revenue -9%, PAT +15%)

1. At a Glance

Welcome to the French bakery of pharmaceuticals – Sanofi India Ltd, where insulin meets incense and EBITDA smells faintly of croissants. The company — market cap ₹10,899 crore, share price ₹4,730 (down 19% in 3 months, classic Gallic shrug) — just dropped its Q3CY25 results. Sales fell 9% YoY, but net profit rose 15%, proving once again that Sanofi doesn’t sell drugs; it sells resilience. With an OPM of 28%, ROE of 47%, and ROCE north of 49%, this French powerhouse could teach even LVMH how to squeeze margin out of medicine.

Despite the price control tantrums of the National List of Essential Medicines (NLEM) and a diabetic market that refuses to behave, Sanofi still maintains aristocratic calm — announcing an interim dividend of ₹75/share, because why not? When you’re this cash-rich, you may as well flex.

So buckle up. We’re diving into the story of a company that’s been selling insulin longer than most of us have been managing ours.

2. Introduction

Once upon a time, in the land of croissants and clichés, a French pharmaceutical giant decided to set up shop in India — the land of chai, jugaad, and cholesterol. Thus was born Sanofi India Ltd, a ₹10,000+ crore entity that’s basically France’s soft power in capsule form.

Fast-forward to 2025 — the company is a quiet beast in the Indian pharma zoo. While others roar about biosimilars and APIs, Sanofi prefers to whisper “Lantus” in your ear and watch your glucose levels drop. Its financial year follows the calendar year (because French people don’t do April-March chaos), and its parent company — Sanofi Global and Hoechst GmbH — owns a comfy 60.4%.

But here’s where it gets spicy. In the past few years, Sanofi India has:

• Divested its neutraceutical division for ₹587 crore (because vitamins aren’t sexy enough),
• Sold off its Ankleshwar plant to Zentiva for ₹320 crore (too sweaty for French standards),
• And recently demerged its consumer healthcare arm into a separate listed entity, Sanofi Consumer Healthcare India Ltd, gifting shareholders a 1:1 share bonanza.

Now, the core business stands lean and clinical — focused squarely on Diabetes, Cardiology, CNS, and Thrombosis, and occasionally allergic sneezes (via Allegra).

3. Business Model – WTF Do They Even Do?

If you think Sanofi is just selling insulin pens, you’ve clearly not peeked into their French recipe book. The company manufactures and sells a wide range of prescription drugs — from diabetes management to heart health and neurology — across India and exports to 28 countries.

Here’s how the pie is sliced (calories not included):

• Products (93%) – Tablets, injections, and formulations for therapy areas like Diabetes (Lantus, Toujeo, Soliqua), Cardiology (Ramipril, Carmada), and CNS (Frisium, Depakine).
• Services (6%) – Distribution and collaboration tie-ups with Indian players like Cipla and Emcure to handle marketing and logistics.
• Others (1%) – Odd pharma oddities and intellectual property receipts.

Its Goa plant — with a whopping capacity of 5 billion+ tablets and 85% utilization — does most of the heavy lifting. 61% of its production is exported, which means Goa’s beaches aren’t the only thing flying abroad.

But the masterstroke is in partnerships:

• Cipla handles its CNS portfolio in India.
• Emcure Pharma takes care of Cardiovascular products.
  Both are on 5-year contracts — a move that allows Sanofi to sip espresso while others hustle.

4. Financials Overview

Commentary:
Revenue slipped thanks to NLEM’s price squeeze, but EBITDA laughed in defiance, rising 11%. The company’s cost discipline is tighter than RBI’s liquidity policy. PAT growth was modest, but dividend payout continues at champagne levels.

5. Valuation Discussion – Fair Value Range Only

Let’s crunch like accountants on caffeine:

Method 1 – P/E Approach

• TTM EPS = ₹155
• Industry average P/E = 33.1
• Sanofi’s own average P/E = 29.5
  → Fair value range = ₹4,500 – ₹5,200

Method 2 – EV/EBITDA

• EV/EBITDA = 19.6x
• EBITDA (TTM) = ₹519 Cr
• EV = ₹10,607 Cr
  → Using range of 17x–22x → Fair EV range = ₹8,823–₹11,418 Cr
  → Implied equity value = ₹4,200 – ₹5,400 per share

Method 3 – DCF (Simplified)
Assume FCF growth of 5% for next 5 years, discount rate 10%, terminal growth 3%.
→ DCF Value ≈ ₹4,600–₹5,300 per share

Fair Value Range: ₹4,200 – ₹5,300 per share

Disclaimer: This fair value range is for educational purposes only and is not investment advice.

6. What’s Cooking –